A Clinical Evaluation Of Amlexanox Oral Pellicles In The Topical Management Of Recurrent Aphthous Unlceration

Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect 20% of the general population. The minor manifestation of the condition is the most common and is characterised by small, shallow, round or oval lesions that are surrounded by a raised erythematous halo and are covered by a grey-white pseudomembrane. Appropriate management of patients with this condition is largely symptomatic and should focus on reducing ulcer duration, relieving pain and reducing or preventing ulcer recurrence.Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been evaluated for the treatment of RAU in a series of robust clinical trials. And in 1996 Aphthasol got the approvement from FDA for the management of RAU.In order to determine the efficacy and safty of amlexanox oral pellicles when applied topically for treatment of RAU, A multicenter, randomized,...